Program
nilotinib
Also written as “Nilotinib”, “AMN107” and “Tasigna”.
Its studies are mostly in Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Gastrointestinal Stromal Tumors · Neoplasms · Leukemia, Myeloid, Chronic-Phase · Leukemia, led by 3 companies.
Drug pageNilotinib: every studyAll 134 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartisits history only | 541 open or running | phase 4since Sep 19, 2008 | May 2, 2005 | Aug 30, 2030phase 4 · NCT04877522 |
| Xspray Pharma ABits history only | 20 open or running | phase 1since Jul 29, 2025 | Jul 29, 2025 | none ahead |
| XSpray Microparticles | 10 open or running | phase 1since Feb 19, 2014 | Feb 19, 2014 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of XSpray Microparticles only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 19, 2014First study: phase 1 study in HealthyFirst studyNCT02068898 · 27 enrolled · United Kingdom
TargetBeta
“Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| imatinibrule | Novartis | phase 4 | 70 |
| asciminibrule | Novartis | phase 4 | 16 |
| olverembatinibrule | Ascentage Pharma Group International | phase 3 | 10 |
| Embibatinib | Hansoh Pharmaceutical Group | phase 3 | 7 |
| TQB3911 | Sino Biopharmaceutical | phase 1 | 1 |
Studies
The one study XSpray Microparticles leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02068898Healthy · United Kingdom | 1 | Completed | Mar 2014 | 27 |
How it is read
Names in the registry
- “Nilotinib”, 35 entries
- “nilotinib”, 9 entries
- “AMN107”, 3 entries
- “Tasigna”, 2 entries
- “Nilotinib (AMN107)”, 2 entries
Codes read as this program: XS003.
Conditions, from the studies’ own filings
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive, 34 studies
- Gastrointestinal Stromal Tumors, 11 studies
- Neoplasms, 2 studies
- Leukemia, Myeloid, Chronic-Phase, 1 study
- Leukemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.